Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products

1 February 2023 – the FDA published draft guidance on the design and conduct of externally controlled trials. Submit comments by 2 May 2023.

This guidance provides recommendations to sponsors and investigators considering the use of externally controlled clinical trials to provide evidence of the safety and effectiveness of a drug product.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /